Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambrisentan in PAH (ARIES-1)
NCT00423748Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2003
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of ambrisentan in pulmonary arterial hypertension (PAH), sponsored by Gilead Sciences. Started Dec 2003; status: completed.
02
Drugs
ambrisentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00423748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00423748.